Political oversight of federal research grants

The White House has abandoned a draft executive order that would have granted political appointees veto power over the National Institutes of Health's $48 billion annual research budget. The reversal, confirmed on September 23, 2026, halts a proposal that would have established an external review board to screen biomedical grants after they cleared traditional scientific peer review.

The board, slated to include Office of Management and Budget Director Russell Vought and NIH Director Jay Bhattacharya, would have required unanimous consent to fund any project, effectively giving the administration a direct mechanism to block research it deemed ideologically misaligned.[1][2]

The retreat followed immediate and bipartisan pushback from congressional appropriators, led by Senator Susan Collins (R-Maine), who chairs the Senate Appropriations Committee. On September 22, Collins sent a formal letter to Vought and Bhattacharya warning that the executive order violated congressional intent and threatened the integrity of federal science. "Imposing a political review on awards that have already been selected through a rigorous scientific and merit-based process undermines the long-standing principle that the government funds awards based on scientific need and merit, rather than political ideology," Collins stated.[3][5]

Democratic leaders on the appropriations committees joined the opposition, framing the proposed order as an unprecedented overreach into medical research. Senator Patty Murray (D-Washington) and Representative Rosa DeLauro (D-Connecticut) publicly warned that the administration was threatening to politicize the federal grant-making process. "NIH funding doesn't belong to Donald Trump — it belongs to the patients and families waiting on the next medical breakthrough," Murray noted in a statement following the initial reports of the draft order.[5]

AI

The proposed executive order emerged from a contentious September 18 Oval Office meeting where administration officials expressed frustration with the NIH's current portfolio. The primary grievance centered on the agency's continued funding of projects that clashed with the president's policy agenda, particularly research involving diversity, equity, and inclusion, or studies examining health disparities among different socioeconomic groups. By requiring unanimous approval from a politically appointed board, a single dissenting vote from the OMB director could have terminated funding for studies at major research universities.[1][3]

This draft order represented the administration's latest maneuver in a yearlong campaign to tighten oversight on federal research dollars flowing to elite academic institutions. Earlier in 2026, the White House attempted to impose a 15 percent cap on indirect research costs, a move that would have severely reduced overhead funding for universities conducting NIH-backed studies. That effort also met resistance from Collins and other lawmakers, who argued it would cripple the operational capacity of research laboratories across the country.[5]

The structural conflict over grant approvals traces back to a broader OMB proposal introduced in May 2026. That rule sought to require political appointees to review all discretionary federal grants to ensure alignment with presidential priorities, while expanding the authority of agencies to terminate ongoing grants mid-cycle. The NIH, which disburses the majority of its budget to external labs investigating cancer, infectious diseases, and neurological disorders, became the primary battleground for this policy shift.[2][3]

AI

Congress temporarily insulated the NIH from these sweeping changes by passing a continuing resolution on September 2, 2026. The funding measure, which keeps the government operating through the autumn, includes a specific provision that blocks the implementation of the OMB's May rule. Collins explicitly noted in her letter that advancing the new executive order would directly undermine the statutory block established by the continuing resolution, potentially jeopardizing future spending agreements.[2][3]

While the immediate threat of the executive order has been scrapped, the underlying tension over scientific independence remains unresolved. The legislative shield provided by the continuing resolution expires on December 11, 2026. Lawmakers, university administrators, and scientific advocacy groups are now preparing for the possibility that the OMB will introduce a narrower oversight mechanism or revive the political review effort once the stopgap funding measure lapses, leaving the exact distribution process for the 2027 fiscal year in question.[1][4]